File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Book Chapter: Chemoresistance in glioma

TitleChemoresistance in glioma
Authors
Issue Date2013
PublisherHumana Press
Citation
Chemoresistance in glioma. In Lee, NP ... (et al) (Eds.), New advances on disease biomarkers and molecular targets in biomedicine, p. 243-270. New York: Humana Press, 2013 How to Cite?
AbstractGlioma remains one of the most aggressive and lethal form of cancer. Despite the best available treatment options including surgical resection, radiotherapy, and chemotherapy, prognosis is poor with a median overall survival of just over 1 year. Most patients would die of tumour recurrences because of their tumours’ intrinsic or acquired resistance against chemotherapy. Researchers have strived to better understand the molecular mechanisms of chemoresistance in glioma by using different experimental models, and to direct targeted therapeutics in an attempt to overcome treatment resistance. Currently, different pathways that can confer drug resistance have been identified including DNA damage repair, drug efflux, hypoxia, cancer stem cells, and microRNAs (miRNAs). This chapter will discuss how modulation of these signalling pathways may potentially lead to the development of novel approaches for the treatment of this condition.
Persistent Identifierhttp://hdl.handle.net/10722/187476
ISBN

 

DC FieldValueLanguage
dc.contributor.authorSun, Sen_US
dc.contributor.authorLee, Den_US
dc.contributor.authorLeung, GKKen_US
dc.date.accessioned2013-08-20T12:50:33Z-
dc.date.available2013-08-20T12:50:33Z-
dc.date.issued2013en_US
dc.identifier.citationChemoresistance in glioma. In Lee, NP ... (et al) (Eds.), New advances on disease biomarkers and molecular targets in biomedicine, p. 243-270. New York: Humana Press, 2013en_US
dc.identifier.isbn9781627034555en_US
dc.identifier.urihttp://hdl.handle.net/10722/187476-
dc.description.abstractGlioma remains one of the most aggressive and lethal form of cancer. Despite the best available treatment options including surgical resection, radiotherapy, and chemotherapy, prognosis is poor with a median overall survival of just over 1 year. Most patients would die of tumour recurrences because of their tumours’ intrinsic or acquired resistance against chemotherapy. Researchers have strived to better understand the molecular mechanisms of chemoresistance in glioma by using different experimental models, and to direct targeted therapeutics in an attempt to overcome treatment resistance. Currently, different pathways that can confer drug resistance have been identified including DNA damage repair, drug efflux, hypoxia, cancer stem cells, and microRNAs (miRNAs). This chapter will discuss how modulation of these signalling pathways may potentially lead to the development of novel approaches for the treatment of this condition.-
dc.languageengen_US
dc.publisherHumana Pressen_US
dc.relation.ispartofNew advances on disease biomarkers and molecular targets in biomedicineen_US
dc.titleChemoresistance in gliomaen_US
dc.typeBook_Chapteren_US
dc.identifier.emailSun, S: ssun@hku.hken_US
dc.identifier.emailLee, D: leederek@hku.hken_US
dc.identifier.emailLeung, GKK: gilberto@hkucc.hku.hken_US
dc.identifier.authorityLeung, GKK=rp00522en_US
dc.identifier.doi10.1007/978-1-62703-456-2_14-
dc.identifier.hkuros218592en_US
dc.identifier.spage243en_US
dc.identifier.epage270en_US
dc.publisher.placeNew Yorken_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats